Fiscal Quarter Calendar 2025 – Summary of Financial Results for First Quarter Fiscal Year 2025 Ended June 30, 2024 For the three months ended June 30, 2024, the Company incurred net losses of $2.7 million compared to $0.9 million . NDA submission to FDA for GTX-104 anticipated in the first half of calendar 2025. Conducted a meeting of STRIVE-ON trial investigators in April 2024. The Company reported a net loss of $2.6 million, .
Fiscal Quarter Calendar 2025
Source : www.calendarpedia.com
2025 USA Fiscal Quarter Calendar Free Printable Templates
Source : www.calendarlabs.com
Fiscal Calendars 2025 Free Printable Word templates
Source : www.calendarpedia.com
Printable 2025 Fiscal Year Calendar Template CalendarLabs
Source : www.calendarlabs.com
Fiscal Calendars 2025 Free Printable Word templates
Source : www.calendarpedia.com
2025 USA Fiscal Quarter Calendar Free Printable Templates
Source : www.calendarlabs.com
Fiscal Calendars 2025 Free Printable Word templates
Source : www.calendarpedia.com
2024 2025 Fiscal Year Quarters Template Free Printable Templates
Source : www.calendarlabs.com
Fiscal Calendars 2025 Free Printable Word templates
Source : www.calendarpedia.com
2025 USA Fiscal Quarter Calendar Free Printable Templates
Source : www.calendarlabs.com
Fiscal Quarter Calendar 2025 Fiscal Calendars 2025 Free Printable Word templates: with NDA Submission on Track for 1H Calendar 2025 Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST . announced today its operating results for the first fiscal quarter ended June 30, 2024 (โQ1 Fiscal 2025โ). LiveOneโs CEO and Chairman, Robert Ellin, commented, โWe are thrilled to announce another .
Author
